Current market catalysts

NuScale Power Stock Broke Out in August. Is It a Buy?

NuScale Power gained 10.1% in August following a brutal July, driven by announcements of AI tools for nuclear design and strong demand from data centers seeking carbon-free energy. However, the company reported a 99% revenue decline in Q2 to just $75,000, continues to burn cash, and remains years away from deploying its first reactor. Commercial execution remains unproven, with the stock trading on speculation pending signed power purchase agreements.

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

Kaplan Fox Encourages Wix.com Ltd. (NASDAQ: WIX) Investors with Significant Losses to Contact the Firm Before September 22, 2026

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Wix.com, Hertz Global Holdings, and Hims & Hers Health on behalf of investors who suffered losses. The Wix lawsuit covers investors from February 19, 2025 to May 12, 2026, alleging the company misrepresented its AI capabilities while costs accelerated. Wix's stock fell 27.1% following disappointing Q1 2026 results. Investors with losses are encouraged to contact the firm before respective deadlines.

Deadline Alert: Simply Good Foods Company (SMPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Simply Good Foods Company (SMPL) faces a class action securities fraud lawsuit alleging the company made false statements about its OWYN acquisition between October 2024 and April 2026. The lawsuit claims management failed to disclose product quality issues from a new pea protein supplier, loss of key personnel, excessive promotional activities, and severe integration problems that caused OWYN sales to contract 17% year-over-year. The stock declined significantly following earnings announcements in October 2025 and April 2026, with a $187 million impairment charge taken against OWYN assets.

SKY BLUE CINEMATIX - ENTERTAINMENT - BRAND INTEGRATION : Two Films. One Global Partnership.

Sky Blue Cinematix has been appointed as the exclusive worldwide brand-integration partner for two upcoming feature films from Tested Films: the action thriller 'Habeas Corpus' and the neo-noir romantic mystery 'Blurred', both directed by Ben Cookson. The partnership will connect international brands with these theatrical productions through in-film integration across all territories.

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.

BUREAU VERITAS – Nouvelle émission obligataire de 700 millions d'euros à échéance septembre 2027 - final terms (en anglais)

Bureau Veritas has successfully completed a bond issuance of EUR 700 million with maturity in September 2034. The company also disclosed its number of shares and voting rights as of August 31, 2026.

Taiwan Semiconductor Just Set a New Company Record. A New All-Time High Stock Price Is Coming

Taiwan Semiconductor Manufacturing (TSMC) has reached new all-time highs in gross profit margins, driven by its dominant position in AI chip fabrication. With over 70% of global chip foundry revenue and strong pricing power, the company's improved profitability suggests the stock could reach new all-time highs, as current valuations don't yet reflect the premium margins of this improved business.

BUREAU VERITAS - EUR 700 million new bond issue maturity September 2034 - final terms

Bureau Veritas successfully completed a EUR 700 million bond issuance with maturity in September 2034. The company also reported its number of shares and voting rights as of August 31, 2026, in compliance with French financial regulations.

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.

S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.

OS Therapies Reports Strong Survival Data for Bone Cancer Treatment

OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.

Google Collaborates With Nevoya, Center For Green Market Activation To Deploy 25 Electric Semi Trucks Between Houston, Dallas Route

Intel Jumps 10% as Analyst Says Musk’s Terafab Could Give Foundry Much-Needed Scale

Intel jumped 7% after Northland upgraded the stock, saying Musk’s Terafab could give its loss-making foundry business much-needed scale.

11 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

Gainers 17 Education & Technology (NASDAQ:YQ) shares moved upwards by 28.1% to $3.74 during Tuesday's regular session. The company's market cap stands at $22.6 million. As per the news, the Q2 earnings

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology (NASDAQ:PDSB)

12 Industrials Stocks Moving In Tuesday's Intraday Session

Gainers Green Circle Decarbonize (AMEX:GCDT) shares rose 100.6% to $0.75 during Tuesday's regular session. The market value of their outstanding shares is at $7.1 million. CEA Industries (NASDAQ:BNC) stock

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Gainers Mobix Labs (NASDAQ:MOBX) shares rose 37.1% to $1.27 during Tuesday's regular session. The company's market cap stands at $16.6 million. Arbe Robotics (NASDAQ:ARBE) shares rose 22.21% to $0.78. The

Boeing Delivers 51 Aircraft In August

Herbalife Launches $250 Million Stock Buyback

Herbalife announces a $250M share buyback, citing attractive valuation and strong cash flow. HLF shares trade higher.

CNBC Halftime Report Final Trades: Freeport-McMoRan, Pinnacle Financial Partners, Cheniere Energy

Citigroup Maintains Neutral on Harley-Davidson, Raises Price Target to $31

Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25

Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

What's Going On With Amgen Stock Tuesday?

AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets

Chevron CFO Eimear Bonner Says Co. Will Double The Number Of Rigs In Venezuela As Part Of Five-Year Plan To Grow Production

'Seoul eyes $22.3b Texas gas project as first under $350b US investment pact' - Korea Herald

Laser Photonics Appoints Timothy A. Peterman Acting CFO, Effective Immediately

Stock of the Day: Is This the Bottom for Fair Issac?

Fair Isaac is oversold and near $920 support after a 17% drop, suggesting a potential rebound as buyers may drive shares higher.

Citigroup Maintains Buy on Saia, Lowers Price Target to $417